Characterizing models for delivery of pharmacogenomic testing: a scoping review.

IF 1.6 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-09-01 Epub Date: 2025-10-14 DOI:10.1080/14622416.2025.2571387

Zeina Waheed, Mary Bunka, Louisa Edwards, Chad Bousman, Alison Hoens, Jehannine J Austin, Stirling Bryan

{"title":"Characterizing models for delivery of pharmacogenomic testing: a scoping review.","authors":"Zeina Waheed, Mary Bunka, Louisa Edwards, Chad Bousman, Alison Hoens, Jehannine J Austin, Stirling Bryan","doi":"10.1080/14622416.2025.2571387","DOIUrl":null,"url":null,"abstract":"Pharmacogenomic (PGx) testing can help guide medication prescribing for a wide range of health indications. The objective of this scoping review was to understand how PGx testing has been clinically implemented and learn from these experiences. Research questions guiding this work were: (1) what different models for delivery of PGx testing have been employed? (2) what are the characteristics of each delivery model? and (3) what are the reported facilitators and barriers associated with each delivery model? A total of 134 articles reported on 125 PGx initiatives spanning 19 countries. Four unique delivery models were identified: sole prescriber-led (n = 45), prescriber-led within an interdisciplinary care team (n = 34), community pharmacist-led (n = 16), and PGx consultation service (n = 30). The unique combination of characteristics, and reported facilitators and barriers yielded distinct strengths and challenges for each identified delivery model. Findings from this review can help inform future implementation planning or expansion of PGx initiatives by presenting different delivery models that may be employed and the corresponding considerations for each approach. This information can help inform future implementers in the selection of one or more approaches that may be most suitable based on their unique contextual needs, and available infrastructures or resources.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"513-527"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12667736/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2571387","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Pharmacogenomic (PGx) testing can help guide medication prescribing for a wide range of health indications. The objective of this scoping review was to understand how PGx testing has been clinically implemented and learn from these experiences. Research questions guiding this work were: (1) what different models for delivery of PGx testing have been employed? (2) what are the characteristics of each delivery model? and (3) what are the reported facilitators and barriers associated with each delivery model? A total of 134 articles reported on 125 PGx initiatives spanning 19 countries. Four unique delivery models were identified: sole prescriber-led (n = 45), prescriber-led within an interdisciplinary care team (n = 34), community pharmacist-led (n = 16), and PGx consultation service (n = 30). The unique combination of characteristics, and reported facilitators and barriers yielded distinct strengths and challenges for each identified delivery model. Findings from this review can help inform future implementation planning or expansion of PGx initiatives by presenting different delivery models that may be employed and the corresponding considerations for each approach. This information can help inform future implementers in the selection of one or more approaches that may be most suitable based on their unique contextual needs, and available infrastructures or resources.

Abstract Image

查看原文本刊更多论文

表征药物基因组学测试交付模型：范围综述。

药物基因组学（PGx）测试可以帮助指导广泛的健康适应症的药物处方。本综述的目的是了解PGx检测是如何在临床上实施的，并从这些经验中学习。指导这项工作的研究问题是：(1)采用了哪些不同的PGx检测交付模式？(2)每种交付模式的特点是什么？(3)与每种交付模式相关的促进因素和障碍是什么？共有134篇文章报道了19个国家的125项PGx倡议。确定了四种独特的交付模式：单独处方者主导（n = 45），跨学科护理团队中处方者主导（n = 34），社区药剂师主导（n = 16）和PGx咨询服务（n = 30）。特点、报告的促进因素和障碍的独特组合为每种确定的交付模式产生了独特的优势和挑战。通过提出可能采用的不同交付模式以及每种方法的相应考虑，该审查的结果可以帮助为PGx计划的未来实施计划或扩展提供信息。这些信息可以帮助未来的实现者根据其独特的上下文需求和可用的基础设施或资源选择一种或多种可能最适合的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.